‫گلوبل ٹائمز: سی پیک پائیدار مقامی معاشی جدّت طرازی کی بنیاد رکھ رہا ہے، جو پورے خطے اور اس کی اندورنی  ترقی کا اگلا منطقی قدم ہے: وزیر اعظم پاکستان

بیجنگ، 23 اگست، 2022/پی آرنیوزوائر/ — چین پاکستان اقتصادی راہداری (CPEC/سی پیک) کی نمو –بین الاقوامی رابطے کا ایک اقدام – پورے خطے اور اس کی اندرونی  منڈیوں کو مربوط کرنے  کے لیے اگلا منطقی قدم ہے، پاکستان کے وزیر اعظم شہباز شریف نے گلوبل ٹائمز کو اپنے ایک حالیہ خصوصی انٹرویو میں بیلٹ اینڈ روڈ انیشیٹو کے فلیگ شپ پروجیکٹ میں تیسرے فریق کی شرکت کے لیے اپنی کُشادہ دِلی کا اظہار کرتے ہوئے بتایا۔

2013 میں اپنے قیام کے بعد سے، سی پیک نے تیز رفتار اور ٹھوس ترقی  کو جاری رکھا ہے۔ شریف نے کہا کہ گزشتہ دہائی کے دوران، سی پیک نے پاکستان میں بجلی اور بنیادی ڈھانچے میں حائل مشکلات  دُور  کرنے میں مدد کی ہے، اس طرح پائیدار اقتصادی جدّت طرازی کی بنیاد رکھی ہے۔

“جیسے جیسے سہ فریقی شراکت میں   اضافہ ہورہاہے، ہم امید کرتے ہیں کہ اہم  ابھرتی ہوئی مارکیٹوں کے سنگم پر، سب کے لئے برابری کے جذبے جس نے ہمیشہ سی پیک کو قوّت  بخشی ہے، کا مظاہرہ کرتے ہوئے مزید مشترکہ دوست پاکستان کے منفرد کردار سے فائدہ اٹھائیں گے۔”

انہوں نے کہا کہ بین الاقوامی رابطے کے اقدام کے طور پر، سی پیک کی ترقی پورے خطے اور اس کی اندرونی مارکیٹوں کو مربوط کرنے کے لیے اگلا منطقی قدم ہے۔

شریف نے کہا کہ سی پیک کا مقصد خطے کو خوشحالی اور استحکام کی مشترکہ کوشش میں متحدکرنا ہے۔ یہ نقطہ نظر کسی کو ہدف نہیں بناتا ہے، اور یہ کسی فریق کو خارج کرنے کی کوشش نہیں کرتا ہے، شریف نے امید کا ظہار کرتے ہوئے  کہاکہ یہ منصوبہ وسیع بین الاقوامی تعاون تحریک کی حوصلہ افزائی جاری رکھے گا اور خطے کے محرومیوں اور تنازعات کے شیطانی چکر کو توڑنے میں مدد گار  ہوگا۔

پاکستان کے وزیر اعظم نے کہا کہ ان نظریات کے ساتھ، سی پیک  کو ایک “خطرہ”  سمجھنے کی کوئی معقول وجہ نہیں  ہوسکتی سوائے ان لوگوں کے جو چیزوں  کو دوسروں کو نقصان پہنچانے کے نقطہ نظر سے دیکھتے ہیں اور یہ چاہتے ہیں کہ “ہمارے لوگ ترقی کے ثمرات سے محروم رہیں”۔

شریف نے کہا کہ پاکستان چین-پاکستان اقتصادی راہداری (سی پیک) کی افغانستان تک توسیع کی حمایت کرتا ہے۔ “امید ہے کہ ہماری کوششیں ایک پرامن، مستحکم، خوشحال، اور مربوط افغانستان کو ہمارے خطے کے استحکام اور طویل مدتی خوشحالی میں کردار ادا کرنے کے حتمی مقصد کے ہمراہ افغانستان کے ساتھ بین الاقوامی تعلقات کے تسلسل کو یقینی بنائیں گی۔”

وزیر اعظم نے یہ بھی کہا کہ انہوں نے گوادر سمیت متعدد سی پیک منصوبوں کا دورہ کیا ہے تاکہ ٹائم لائنز کی تکمیل کو یقینی بنایا جا سکے۔ سی پیک کے زیر تکمیل منصوبوں کی بروقت تکمیل دوطرفہ اقتصادی تعاون کے مستقبل کے ایجنڈے کے لیے ہمیشہ سے ان کی ترجیح رہی ہے۔

انہوں نے کہا کہ فصل کے ابتدائی مرحلے کی کامیابی کے بعد، سی پیک تیزی سے حقیقت میں ڈھل رہا ہے۔

لنک: https://www.globaltimes.cn/page/202208/1272927.shtml

Global Times: CPEC laying foundation for sustained indigenous economic modernization; growth within and across the region is logical next step: Pakistan PM

BEIJING, Aug. 23, 2022 /PRNewswire/ — The growth of China-Pakistan Economic Corridor (CPEC) – an international connectivity initiative – to connect markets within and across the region is the logical next step, Pakistan Prime Minister Shehbaz Sharif told the Global Times in a recent exclusive interview, expressing his openness to third-party participation to the flagship project of Belt and Road Initiative.

Since its inception in 2013, the CPEC has continued to make rapid and tangible progress. Over the past decade, CPEC has helped Pakistan alleviate power and infrastructure bottlenecks, thus laying the foundation for sustained economic modernization, Sharif said.

“As third-party participation picks up, we expect more common friends to benefit from Pakistan’s unique role at the crossroads of major emerging markets, demonstrating the win-win spirit that has always animated CPEC.”

As an international connectivity initiative, CPEC’s growth to connect markets within and across the region is the logical next step, he said.

Sharif said CPEC aims to bring the region together in the shared pursuit of prosperity and stability. This approach is not targeted at, and does not seek to exclude any party, Sharif said, hoping the project would continue to inspire greater international cooperation and help the region break the vicious cycle of deprivation and conflict.

With these ideals at its core, CPEC cannot reasonably be perceived as a “threat” except to those who view things in a zero-sum perspective and would rather “want that our peoples remain deprived of the fruits of development”, the Pakistan prime minister said.

Pakistan supports extension of China-Pakistan Economic Corridor (CPEC) to Afghanistan, Sharif said. “It is hoped that our efforts will ensure continuity of international engagement with Afghanistan with the eventual aim of seeing a peaceful, stable, prosperous, and connected Afghanistan contributing to the stability and long-term prosperity of our region.”

The prime minister also said he has visited numerous CPEC projects, including in Gwadar, to ensure that timelines are met. Timely completion of underway CPEC projects serve as the building blocks for the future agenda of bilateral economic cooperation has always been his priority.

Following the success of its early-harvest phase, CPEC is becoming increasingly substantiated, he said.

https://www.globaltimes.cn/page/202208/1272927.shtml

CBI Index 2022 offers a glimpse into the future of the citizenship by investment industry: CS Global Partners

London, Aug. 22, 2022 (GLOBE NEWSWIRE) — The world’s most definitive guide on citizenship by investment, the CBI Index, was published today by PWM Magazine, a publication from the Financial Times in collaboration with CS Global Partners and offers readers a view of an industry in metamorphosis.

Released amid a year that has, again, been marked by heightened uncertainty, increased security risk, political instability and intensifying calls to act on the global warming threat, the CBI Index comes at a time when most individuals are reassessing the base they call home and are looking for more stable environments that not only offer security but business, health and education opportunities for generations to come.

Despite a tumultuous global environment and an investment industry harrowed by scrutiny from the EU and USA, this year’s CBI Index hints at opportunity amidst the chaos – opportunity for the CBI industry to evolve and perhaps be the answer to those who look to it to harness the world’s offerings.

Often thought of as a Plan B, the CBI Index infers that in a post-pandemic reset, there has been a shift in trust away from government as individuals obtain second, or multiple citizenships, and take control of their destinies. The new global citizen will look to invest in ‘Plan A’ and a more positive future for people and planet.

While the CBI Index is a rating system designed to measure the performance and appeal of global citizenship by investment (CBI) programmes across a diverse range of indicators, it is also a voice for the industry and a forward-looking manual that offers readers a glimpse of what the industry could be provided that industry players come together and shape its regulatory environment to benefit not only host countries, but citizens around the world who have realised that home need not be their place of birth, but where opportunities lie.

This Index is intended as a practical tool, both for those who wish to compare CBI programmes as a whole and for those who wish to compare specific aspects of each programme.

Its purpose is to provide a rigorous and systematic mechanism for appraising programmes, to facilitate the decision-making process for individuals considering them, and to bring value to the CBI industry.

The CBI Index assesses all countries with operational CBI programmes, which, in 2022, include Antigua and Barbuda, Austria, Cambodia, Dominica, Egypt, Grenada, Jordan, Malta, Montenegro, St Kitts and Nevis, St Lucia, Turkey and Vanuatu.

The CBI Index rates CBI programmes according to these nine pillars: Freedom of Movement, Standard of Living, Minimum Investment Outlay, Mandatory Travel or Residence, Citizenship Timeline, Ease of Processing, Due Diligence, Family and Certainty of Product.

Freedom of Movement measures the relative strength of each country’s citizenship based on three equally weighted factors: the number of destinations to which a country’s passport allows travel without restriction, the number of prime business hubs to which it provides access, and the degree to which a given citizenship provides settlement rights in other nations.

The Standard of Living pillar is a measure of the quality of life offered by the 13 CBI jurisdictions under assessment and this pillar is vital to those who yearn to relocate and secure a prosperous and fulfilling lifestyle. Similarly, it is key to those wanting to take advantage of local business opportunities or needing to transfer and safeguard their assets.

The Minimum Investment Outlay pillar measures one of the most practical and foremost considerations of CBI – how much capital is required for the investor to become an eligible applicant for the programme of their choosing. The cost of applying for CBI increases with the number of dependants — or qualifying family members — included in an application. In some jurisdictions this increase is proportional, while in others the cost only increases following the inclusion of multiple dependants.

Mandatory Travel or Residence examines the travel or residence conditions imposed on applicants both before and after the granting of citizenship.

The Citizenship Timeline pillar looks at the average time taken for citizenship to be secured by the applicant.

The Ease of Processing pillar measures the end-to-end complexity of the CBI application process. In some jurisdictions, the application process can be a labour-intensive and painstaking task that is time-consuming for the applicant; in others, it is streamlined, and the applicant receives clear directives on how to proceed. The overall effortlessness of the application process is a particularly important component, and the promise of a smooth, hassle-free process can generate readiness to engage with a programme.

The Due Diligence pillar focuses on each nation’s commitment to ensuring that their programme remains transparent and effective at evaluating potential candidates for citizenship. It is therefore a measure of each programme’s integrity.

The Family pillar measures the extent to which investors can obtain citizenship for their immediate and extended family. The CBI Index recognises that the rise of increasingly complex family relationships is driving investors to seek programmes that allow for a more diverse range of family members to be included under a primary application.

Lastly, Certainty of Product encompasses a range of factors that measure a programme’s certainty across five different dimensions: longevity, popularity and renown, stability, reputation and adaptability. Additionally, it assesses a programme’s responsiveness to major global events, such as the Covid-19 pandemic and the war in Ukraine that have had a significant impact on global mobility and due diligence requirements.

As the CBI industry undergoes its own challenges and metamorphosis, the CBI Index gives worldly investors a reliable analysis of reputable programmes that will enable them to choose second citizenship in destinations that will fulfil their needs.

Download the full report here to see which of the thirteen countries took top spot and gain further insight into the CBI industry.

PR CS Global Partners
CS Global Partners
+44 (0) 207 318 4343
mildred.thabane@csglobalpartners.com

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Outset Medical, Inc. Investors With Losses to Secure Counsel Before Important September 6 Deadline in Securities Class Action – OM

NEW YORK, Aug. 20, 2022 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Outset Medical, Inc. (NASDAQ: OM) between September 15, 2020 and June 13, 2022, both dates inclusive (the “Class Period”), of the important September 6, 2022 lead plaintiff deadline.

SO WHAT: If you purchased Outset Medical securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Outset Medical class action, go to https://rosenlegal.com/submit-form/?case_id=6976 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 6, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) defendants had “continuously made improvements and updates to Tablo over time since its original clearance” that required an additional 510(k) application; (2) as a result, Outset Medical could not conduct a human factors study on a cleared device in accordance with FDA protocols; (3) Outset Medical’s inability to conduct the human factors study subjected Outset Medical to the likelihood of the FDA imposing a “shipment hold” and marketing suspension, leaving the Company unable to sell Tablo for home use; and (4) as a result, defendants’ positive statements about Outset Medical’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Outset Medical class action, go to https://rosenlegal.com/submit-form/?case_id=6976 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Solana Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – SOL

NEW YORK, Aug. 20, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of SOL tokens (“SOL securities”) between March 24, 2020 and the present, inclusive (the “Class Period”), of the important September 6, 202 lead plaintiff deadline in the securities class action lawsuit against Solana Labs, Inc., the Solana Foundation, Anatoly Yakovenko, Multicoin Capital Management LLC, Kyle Samani, and FalconX LLC (together, “Defendants”).

SO WHAT: If you purchased SOL securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the SOL class action, go to https://rosenlegal.com/submit-form/?case_id=7539 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 6, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, Solana issues securities that are required to be, but are not, registered with the U.S. Securities and Exchange Commission. Throughout the Class Period, defendants promoted SOL securities (SOL tokens) and sold them to investors, who has suffered losses from purchasing SOL securities.

To join the SOL class action, go to https://rosenlegal.com/submit-form/?case_id=7539 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

NOTV FINAL DEADLINE AUGUST 22: ROSEN, A LEADING LAW FIRM, Encourages Inotiv, Inc. Investors to Secure Counsel Before Important Monday Deadline in Securities Class Action Filed by the Firm – NOTV

NEW YORK, Aug. 19, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Inotiv, Inc. (NASDAQ: NOTV) between September 21, 2021 and June 13, 2022, both dates inclusive (the “Class Period”), of the important August 22, 2022 lead plaintiff deadline in the securities class action commenced by the firm.

SO WHAT: If you purchased Inotiv securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Inotiv class action, go to https://rosenlegal.com/submit-form/?case_id=6426 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 22, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose: (1) Envigo RMS, LLC (“Envigo”) and Inotiv’s Cumberland, Virginia facility (the “Cumberland Facility”) engaged in widespread and flagrant violations of the Animal Welfare Act (“AWA”); (2) Envigo and Inotiv’s Cumberland Facility continuously violated the AWA; (3) Envigo and Inotiv did not properly remedy issues with regards to animal welfare at the Cumberland Facility; (4) as a result, Inotiv was likely to face increased scrutiny and governmental action; (5) Inotiv would imminently shut down two facilities, including the Cumberland Facility; (6) Inotiv did not engage in proper due diligence; and (7) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Inotiv class action, go to https://rosenlegal.com/submit-form/?case_id=6426 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Enochian BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ENOB

NEW YORK, Aug. 19, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Enochian BioSciences, Inc. (NASDAQ: ENOB) between January 17, 2018 and June 27, 2022, both dates inclusive, (the “Class Period”), including common stock issued by Enochian in a private placement offering on or about February 16, 2018, of the important September 26, 2022 lead plaintiff deadline.

SO WHAT: If you purchased Enochian BioSciences securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Enochian BioSciences class action, go to https://rosenlegal.com/submit-form/?case_id=6517 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 26, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) co-founder and inventor, Serhat Gumrukcu, was engaged in a variety of frauds; (2) Gumrukcu was not a licensed doctor anywhere in the world; (3) as a result of the foregoing, Gumrukcu’s purported contributions to Enochian lacked a reasonable basis; (4) as a result of the foregoing, Enochian had overstated its commercial prospects; (5) Gumrukcu had improperly diverted approximately $20 million from Enochian to entities he owned; and (6) as a result of the foregoing, defendants’ positive statements about Enochian’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Enochian BioSciences class action, go to https://rosenlegal.com/submit-form/?case_id=6517 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

        Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

COIN NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Coinbase Global, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – COIN

NEW YORK, Aug. 19, 2022 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Coinbase Global, Inc. (NASDAQ: COIN) between April 14, 2021 and July 26, 2022, both dates inclusive (the “Class Period”). If you wish to serve as lead plaintiff, you must move the Court no later than October 3, 2022.

SO WHAT: If you purchased Coinbase securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Coinbase class action, go to https://rosenlegal.com/submit-form/?case_id=8095 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 3, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Coinbase custodially held crypto assets on behalf of its customers, which assets Coinbase knew or recklessly disregarded could qualify as the property of a bankruptcy estate, making those assets potentially subject to bankruptcy proceedings in which Coinbase’s customers would be treated as the Company’s general unsecured creditors; (2) Coinbase allowed Americans to trade digital assets that Coinbase knew or recklessly disregarded should have been registered as securities with the SEC; (3) the foregoing conduct subjected the Company to a heightened risk of regulatory and governmental scrutiny and enforcement action; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Coinbase class action, go to https://rosenlegal.com/submit-form/?case_id=8095 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages LifeStance Health Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – LFST

NEW YORK, Aug. 19, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of LifeStance Health Group, Inc. (NASDAQ: LFST) pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued in connection with LifeStance Health’s June 2021 initial public offering (the “IPO”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 11, 2022.

SO WHAT: If you purchased LifeStance Health securities pursuant and/or traceable to the Registration Statement you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the LifeStance Health class action, go to https://rosenlegal.com/submit-form/?case_id=8073 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 11, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, the IPO Registration Statement featured false and/or misleading statements and/or failed to disclose that: (1) the number of virtual visits clients were undertaking utilizing LifeStance Health was decreasing as the COVID-19 lockdowns were being lifted, thereby flatlining LifeStance Health’s out-patient/virtual revenue growth; (2) the percentage of in-person visits clients were undertaking utilizing LifeStance Health was increasing as the COVID-19 lockdowns were being lifted, thereby causing LifeStance Health’s operating expenses to increase substantially; (3) LifeStance Health had lost a large number of physicians due to burn-out and, as a result, its physician retention rate had fallen significantly below the 87% highlighted in the IPO’s registration statement and LifeStance Health had been expending additional costs to onboard new physicians who were less productive than the outgoing physicians they were replacing; and (4) as a result, LifeStance Health’s business metrics and financial prospects were not as strong as the IPO’s registration statement represented. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the LifeStance Health class action, go to https://rosenlegal.com/submit-form/?case_id=8073 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Carvana Co. Investors to Secure Counsel Before Important Deadline in Securities Class Action Initiated by the Firm – CVNA

NEW YORK, Aug. 19, 2022 (GLOBE NEWSWIRE) — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Carvana Co. (NYSE: CVNA) between May 6, 2020 and June 24, 2022, both dates inclusive (the “Class Period”), of the important October 3, 2022 lead plaintiff deadline in the securities class action commenced by the firm.

SO WHAT: If you purchased Carvana securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Carvana class action, go to https://rosenlegal.com/submit-form/?case_id=6457 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 3, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Carvana faced serious, ongoing issues with documentation, registration, and title with many of its vehicles; (2) as a result, Carvana was issuing unusually frequent temporary plates; (3) as a result of the foregoing, Carvana was violating laws and regulations in many existing markets; (4) as a result of the foregoing, Carvana risked its ability to continue business and/or expand its business in existing markets; (5) as a result of the foregoing, Carvana was at an increased risk of governmental investigation and action; (6) Carvana was in discussion with state and local authorities regarding the above-stated business tactics and issues; (7) Carvana was facing imminent and ongoing regulatory actions including license suspensions, business cessation, and probation in several states and counties including in Arizona, Illinois, Pennsylvania, Michigan, and North Carolina; and (8) as a result, defendants’ statements about Carvana’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Carvana class action, go https://rosenlegal.com/submit-form/?case_id=6457 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

        Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Ampio Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AMPE

NEW YORK, Aug. 19, 2022 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) between December 29, 2020 and August 3, 2022, both dates inclusive (the “Class Period”). If you wish to serve as lead plaintiff, you must move the Court no later than October 17, 2022.

SO WHAT: If you purchased Ampio Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Ampio Pharmaceuticals class action, go to https://rosenlegal.com/submit-form/?case_id=8201 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 17, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose material adverse facts about the Company’s business operations and prospects. Specifically, defendants: (1) inflated the Company’s true ability to successfully file a Biologics License Application (BLA) for Ampio; (2) inflated the results of the AP-013 study of Ampion (the Company’s lead product with “unique immunomodulatory action and anti-inflammatory effects” used to treat individuals with inflammatory conditions including, but not limited to, severe osteoarthritis of the knee (OAK)) and the timing of unblinding the data from the AP-013 study; and (3) that, as a result, of the foregoing, defendants’ statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Ampio Pharmaceuticals class action, go to https://rosenlegal.com/submit-form/?case_id=8201 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

 

Nyxoah to Participate in the 17th Annual Wells Fargo Securities Healthcare Conference

Nyxoah to Participate in the 17th Annual Wells Fargo Securities Healthcare Conference

Mont-Saint-Guibert, Belgium – August 18, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the 17th Annual Wells Fargo Securities Healthcare Conference, which takes place September 7-9, 2022, in Everett, MA. Nyxoah management will host one-on-one meetings with investors on Friday, September 9.

Nyxoah’s updated Investor Presentation can be accessed on the Shareholder Information section of the Company’s Investor Relations page.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Contacts:
Nyxoah
Loic Moreau, Chief Financial Officer
corporate@nyxoah.com
+32 473 33 19 80

Jeremy Feffer, VP IR and Corporate Communications
jeremy.feffer@nyxoah.com
+1 917 749 1494

Attachment